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The mechanism of the antiproliferative activity of 
tamoxifen on melanoma cells in vitro and in vivo is 
poorly understood, as it is not mediated by the 
antiestrogenic properties of tamoxifen. Using a 
whole-cell assay and nuclear and cytosolic radio-
binding experiments with eHJ-estradiol as tracer, we 
found that MNT1, M10, and M14 melanoma cell lines 
as well as primary tumors expressed type II estrogen 
binding sites that bind tamoxifen and the flavonoid 
quercetin with similar affinity (K0 10-25 nM). Cell 
count and clonogenic assay showed both compounds 
to inhibit melanoma cell growth in a concentration-
dependent manner in the range of concentrations 
I n addition to the high-affinity, low-capacity estrogen recep-tor (ER), rat and human target tissues contain a second binding macromolecule tem1ed type II estrogen binding sites (EBS). Although these sites display the same steroid speciftcity of ER, they exhibit lower affinity but higher 
capacity for the ligand than ER [1 ,2). At present, the role of type JI 
EBS has not been defined completely. Because of the relatively low 
affinity (apparent di ssociation constant [K0 ) of approximately 20 
nM) of type II EBS for estrogens, it is not clear whether these sites 
could be occupied by estrogens in vivo . A new explanation of the 
possible function of type H EBS comes from the demonstration that 
these sites in rat ute rine nuclei are occupied ;,., vivo by a flavonoid-
like molecule with growth-inhibitory activity [3,4). 
Flavonoids are a widely distributed class of natural substances 
with a variety of biologic actions [5). It has been found that 
flavonoids, in particular quercetin , bind to type II EBS present in 
human m amm ary [3], ovarian [6), colorectal [7) , m eningeal [8], and 
leukemic [9) tumor ceUs and inhibit ceU growth, probably by 
mimicking the endogenous ligand . ln addition to quercetin, we 
found that the antiestrogen tamoxifet1 is able to compete in 
whole-ceU assays for type II EBS and to exert a concentration-
dependent inhibition of cell proliferation in a multidrug-resistant, 
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between 1 nM and 1 ~-tM. Neither the pure antiestro-
gen ICI-182780 nor the 3-rhamnosylglucoside of 
quercetin, rutin, bound to type II estrogen binding 
sites or inhibited cell growth. Our results suggesting 
that tamoxifen and quercetin can inhibit melanoma 
cell growth by interacting with type II estrogen bind-
ing sites help explain the reported effectiveness of 
tamoxifen, particularly in estrogen-receptor-nega-
tive tumors, and stress the potential role of quercetin 
in the treatment of melanoma. Key 111ords: flavonoids/ 
estrogen receptorlarrtiestrogens/a.ntit11mor agent.] Invest Der-
matol 105:248-253, 1995 
ER-negative MCF-7 breast cancer cell line [10] and in the IM-9 
lymphoblastoid ceU line expressing bothER and type II EBS [11). 
After the fi rst report on a chemo-honnonal therapy regimen for 
the treatment of patients with melanoma [12), more recent clinical 
fi.ndings from different investigators have indicated that the addition 
of tamoxifen to the combination chemotherapy markedly increases 
the response rate in these patients [13-17). It has also been observed 
that the antiproliferative effect of tamoxifen on human melanoma 
cells is not mediated by an anticstrogenic effect on ER [18) . These 
observations prompted us to test human melanoma ceUs for the 
presence of type II EBS to evaluate whether type II-mediated 
growth inhibition can be one of the mechanisms through which 
tamoxifen is effective in melanoma therapy. 
MATERJALS AND METHODS 
Cell Lines and Tumor Specimens The human cell lines M 10, M1 4 
[19] , and MNTl [20] were derived from metastatic melanoma nodules. 
Melanoma cells were grown as monolaycrs in 75-cm 2 T-Aasks in RPMI 
1640 culture medium (Gibco, Paisley, UK) supplemented with lO'Yo heat-
inactivated fetal bovine serum (FBS) (Gibco) and 2 mM glu tamine. Some 
experiments were also performed using Rl'MI 1640 medium without 
phenol red (Eurobio, Les Ulis, France) and with or without charcoal/ 
dextran-treated FBS. 
Fresh tissue specimens, collected at surgery from two female patients, 
were frozen in liquid nitrogen and stored at - 80°C until assay. The patients 
were affected by nodular melanoma of the vulva (case A, age 44 years) and 
of the leg (case B, age 72 years). 
Drugs and Chemicals Quercetin (3,3' ,4' ,5,7-pentahydroxy-Aavone) 
and rutin (3-rhamnosylglucoside of quercetin) were purchased from Aldrich 
(Steinhein, Gcm1any). Steroid hormones were obtained from Sigma (Dei-
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senhofcn, Germany). Tamoxitcn (trnl/s-2 [4-( 1.2-diphcnyl-'1 -butenyl)phc-
noxy]-N ,N-dimethyl-ethylaminc) and IC I-1.82780 (7a-[9-(4,4,5.5 ,5-penta-
fluoro-pcntyl-sulfiny l)-nonyl]estra-5,3,5 ,(1 0)-tricne-3, 17{3-diol) were a g ift 
from Zencca Phamwceuti ca ls (Milano, Italy). 
Growth Experiments Cells were plated at 1 0'1/cm2 in 16-mrn we lls of a 
24-wel l plate (Falcon; 13ecton Dickinson, Oxnard. CA) . After 18 h. the 
medium was replaced with fresh medium contain ing the compounds to be 
tested. The compounds were added from an abso lute-ethanol stock solu-
tion, and th e control c ells were treated ·with the san1c arnount of vehicle 
alone . T he final ethanol concentration IH!Ver exceeded 1 •y., (v /v) either in 
control or in treated samples. T he treatments were repeated after 24 h. 
Q uadrupli cate hemocytometer counts of trip li cate cultures we re performed 
afte r 48 h of exposure to the compounds. 
Culture Assay for Colony-Forming Cells Cell s were cultured as 
described by Hamburger and Sa lmon [21 ]. BrieHy, ·1 ml of underlayer, 
C0111poscd of 0 .511'11 agar in lscovc-tnodificd Dulbccco's tn cdilll11 w ith l0%1 
FBS, 200 IU/ml penkillin, aud the compounds to be tested, was plated in 
5-cm plastic Petri dishes. Ce ll s were suspended in 0.3% aga r in the lscovc 
medi llln supp lc tnented as above and contajn in g the drugs to be tested at the 
indicated concentrations. Each culture rece ived 0.5-1.5 X ·1 03 cells/mi. 
Cultures were incubated at 37°C in a 7.5'Yo CO,-humified atmosphere and 
were cxa tnincd \vith an in verted-phase n1icros~opc. T he colon ies (coll ec-
tion of 30 or more cell s) were counted 1 () d after plating. 
ER Analysis Cells in 24-well plates (4-8 X 1 o·' cell s/well) in R.J>MI 
1.640 medium supplemented w ith 20 mM HEPES without serum were 
incubated with increas ing concentratio ns (0.1-2 .0 nM) of 2,4,6,7-["1-1]-
estradiol (Amcrsham , Little Chalfo nt , UK; specific activity 85-11 0 C i/ 
mmol) alone or in the presence of a J 00- fo ld excess of unlabeled diethyl-
s tilbestrol for 30 min at 3 7°C in a 5% CO,-a ir atmosphere. Pre liminary 
experiments had shown that this time intcn~d exceeded that required for 
the achievement of ma:-cimal bi11ding. Spcciric binding was calculated as the 
difference between total binding (uncompeted wells) and nonspecific 
binding (competed wells) . The concentra tio n and apparent equi librium 
di ssociation constant (K0 ) of receptor sites we re obtained by Scatchard 
ana lysis. The conversion of radioactivity (dpm) to number of sites per ce ll 
was accomplished by dete rmining the amoun t of [' H)-estradiol bound for 
aliquots deri ved from a known mnnber of cell s and then applying Avo-
gadro's number. ERs in metastatic melanoma specimens were assayed using 
the dextran-coa ted charcoa l me thod, as described previously r9J. The 
observed number of bind.ing sites was expressed as final of ['H]-Iigand 
specifi cally hound per mg of cytosolic protein. 
Type II EBS Analysis Cells were analyzed for type ll EllS by a 
wbole-cc ll ass">'• as described previously J'22] w ith slight modifications. 
BrieAy, 2-5 X 1 o·' cells/weB in 24-well plates in medium w ith 20 mM 
HEPES w ithout serum were incubated at 4°C for 2.5 h with increasing 
concen trations (4-60 nM) of 6,7-['1-1]- estradio l (Amcrsham; specific activ-
ity 40-60 Ci/mmol) alo ne or in the presence of a 200-fold molar excess of 
un labeled diethylstilbestrol. The cells were washed tw ice with icc-cold 
medium and th en resuspended in 0.8 ml 80% (v/v) abso lu te ethano l to 
extract bound steroid. Specific binding was calcula ted as the difference 
between total and no nspecific binding. T he results were expressed as the 
number of binding sites per cell . Cytosolic type 11 EllS in tumor specimens 
was assayed by the hydroxyapatite method. as described f22]. To determ ine 
the effect that sulfh ydryl reduction has on type II EllS, we pre- incubated the 
cytosol with 10 mM dithiothrcitol for 1 hat 4°C. Nuclear type II EllS was 
assayed accord ing to the p rocedure developed by Sync et nl (l) , with minor 
modifications. 13rieHy. the tissue was homogen.ized (200-500 mg/ml) in TE 
buffc1: (10 mM Tris. 1.5 mM ethylcnediaminctetraacctic acid , pH 7.4) at 
4 °C, and the homogenate was centrifuged at 2000 X g for 30 min. The 
pellet was then resuspended in the same buffer and used for the sucrose pad 
nuclear exchange assay. O ne-milliliter aliquots of ho nwgenate we re layered 
onto 1-ml pads of1.2 M sucrose and ccntr;fuged in a swinging-bucket rotor 
a t 7000 X g for 45 min at 4°C . T he supernatant and the sucrose pad were 
discarded, and the nuclear pellet was incubated in the presence of increasing 
concentrations (4-60 nM) of l-'1-1]-estradiol (Amcrsham; specific activity 
40 -60 C i/ mmol) alone or in the presence of a 300-fold molar excess of 
unlabeled dicthylstiibcstrol for 60 min at 30°C. At the end of the incubation 
period, the tubes were chilled o n ice for 5 111in. Electron 1uicroscopic 
observatio ns of the nuclear preparations did not reveal ;my contaminating 
r im of cytoplasmic material around nuclei. Receptor-stero id complexes 
were then separated &on1 free steroid by precipita tio n with cold protatninc 
sulfate (1 mg/ ml) in T E bufFer for 10 min at 4°C. T he samples wew theu 
di luted with 6 ml of TE buffer containing 1% Tween 80 (Si~o:ma) ;md 
centrifuged at 2000 X g fo r ·1 0 min. The resul ti ng pe ll ets were was hed once 
w ith 6 ml of the same bufFer and then extracted overn ight with 1 ml of SO% 
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F igure 1. M14 cells express type II EBS . MJ-1 ceLl s were anal yzed for 
type fl EIJS by the whole-cell assay. BrieAy, 2-5 X 1 o·' cell s/well in 24- wcll 
plates in medium with 20 mM HE PES without Sl!rum were incubated at 4°C 
for 2.5 h with increasing concentrations (4-60 nM) of 6.7-[' H]-estrad iol 
(Amersham; specific activity 40 -60 Ci/mmol) alone or in the presence of a 
200-fo ld molar excess of unlabded diethylstilbestrol to detcm1ine tota l (npeu 
circles) and nonspecifi c (trinn,gles) binding, respective ly. The ce ll s were 
washed twice with icc-cold medium and then resuspended in 0.8 ml 80% 
(v/v) abso lute ethanol to extract bound stero id. The specific binding (closed 
circles) was calcula ted :ts the difference be tween coral and nonspecific 
binding. T he results were expressed as the number of binding sites per celL 
n) Saturation anal ysis; b) Scatchard plot of da ta in (t1). 
ethanoL Radioactivity was measured by liquid sc indllation spectrom etry. 
Specifi c binding was ca lculated as the difFerence between binding in the 
absen ce (total binding) and in the presence of diethylstilbestrol (nonspecific 
binding) and is reported as bound fi11o l/ mg of nuclear DNA. DNA 
concentration in nuclear preparations \Vas assayed using the n1 cthod de-
scribed by Burton [23]. 
RESULTS 
Melanoma Cell Lines Express ER and Type II EBS Evidence 
ofER and type 11 EBS binding of[-'H]-estradiol in MNT-1, MlO, 
and M 14 cell Lines was observed by saturation analysis over a broad 
range of tracer con cen trations in whole-cell assays. T he CHJ-
estradio l saturation analysis carried out on M14 cell s at 4°C for 2.5 
h resulted in a sigmo id curve, w ith saturation occurring at CHJ-
estradio l con centratio n s of30 nM or greater (Fig la). As predicted 
from the b.iphasic nature of the saturation c urve, Scatchard analysis 
[24) of the binding va lues yielded a con cave plot (Fig lb) similar to 
tha t observed in other tissues [1 ,22]. Because an accun1te es timate 
of both the KD value and the numbe r of type Il EBS cannot be 
made from a c urvilinear Scatcha rd plot, these parameters were 
obtain ed from the saturation c urv e. For the experimen t sh own in 
Fig 1, t h e number of type II EBS in M14 cell s, ca lculated at 
maximal binding, was 1250 X 10 - 3 sites/ celL T h e correspondin g 
KD value, determined from t he [-'H)-es tradiol con centration re-
qui,·ed tor h a lf-ma ximal saturation, was about 10 nM. Hill ana lysis 
of these data yielded a Hill coeffic ient of greater th <U1 2. Although 
the res ults arc not conclusive, the con cave Scatchard plot and Hil l 
coefficient for these sites suggest that they are multiple and display 
positive coopcrativ ity . T he results of four similar experimen ts 
performed o n MNTI, M10, and M14 cell lines arc reported in 
Table I. 
To avoid the interference of type II EBS in ER m easure ment and 
to allow [3 H]-cstradiol exchange with occupied ER, we performed 
titration ana lys is ofER in sepanJte experiments at 37°C for 30 min 
w ith ['H)-estradiol concentration s in th e range of 0.1 to 2 .0 nM. 
A ll three cell lin es expressed ER with KIJ va lues ranging from 0.3 
w 0.6 nM (Table 1). 
Steroid specificity experimen ts demonstrated tha t ER and type I! 
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Table I. Human Melanoma Cell Lines Express ER and 
Type II EBS" 
ER Type II EBS 
CeU 
Line Sites/Cell X 10- 4 K0 (nM) Sites/Cell X 1 o-" K 0 (nM) 
MNTI 6.76 ± 0.72 0.3 ± 0.2 206 ± 351' 15 ± 4 
M IO 5.25 ± 0.48 0.4 ± 0.1 153 ± 27 12 ± 5 
M14 3.55 ± 0.55 0.6 ± 0.2 "139 ± 12 13 ± 4 
·• !=o r procedures . sec tvlnrerit1ls fl/1(1 !v/ct iJ Cids . Spccifac binding wn s calcu lated as the 
difference between totnl and nonspecific bind ing. Resul ts are expressed as th e number 
o f binding sites per cciJ. 
J. Rcsui[S arc ex pressed as mean ::!:: SO o f tOur dilfcrcnt experimen ts. 
EBS in melanoma cell lines are estrogen specifi c . O nly those 
steroids with estrogenic activity i..t1.h.ibited binding of eHJ-estradiol 
to ER and type II EBS (Ta ble II). Data in Table II show that both 
quercetin and tamoxifen were able to compete w ith e r-T]-estradiol 
for type ll EBS, with a potency simil ar to that of di ethylstilbestro l. 
On the con trary, the 3-rhamnosylglucoside ofquercetm , rutin, and 
the pure antiestrogen ICI- 182780 did not com pete for type II EBS 
binding. As expected , both antiestrogens tamox ifen and IC l-
1.82780 mteracted with ER, w h ereas querce tin and rutin did not. 
Tamoxifen and Quercetin Inhibit Melanoma Cell Growth 
Because m elanoma cells contain type II EBS, it seemed possible that 
they would be sensitive to quercetin. Indeed, not only querceti..t1 
but also tamoxifen at a concentration between 10 - 'J and 10- 6 M 
inhibited the prolife rative activi ty of these cells in a concentration-
de pendent m anner (Fig 2) . ln addition, the magnitude of the 
growth-inhibitory effects of quercetin, tamoxifen, and diethylstil-
bestrol (data not shown) was similar. T he potency of quercetin and 
tamoxifen i.n inhibiting cell growth , however, varied in the cell 
lines tested . MNTl ceUs were the most sensitive, as their g rowth 
was inhibi ted so•;., by quercetm and tamoxifen at con centrations o f 
7 nM and 9 nM, respectively (Fig 2) . Rutin and JC I-1 82780, which 
did not bind to type II EBS, were in effective in inhibiting cell 
growth (Fig 2). 
Despite a 20% reductio n of the cell number at the end of the 
incubation period in cultures supplemented with charcoal/ dextran-
stripped FBS, we o bserved no modifi cations of the activi ty of the 
vario us molecules tested (data not show n) . On the other hand, the 
growth pattem of melanoma cells was not m odified by removing 
phenol red from the medium [25) , and diethylstilbestrol, at con-
centrations able to saturate Ell, had no effect on plating efficiency 
or proliferation of celll.i..t1es in the absence of phen o l red (data not 
shown). Moreover, the i..t1hibitory effec ts oftamoxifen and qu erce-
Table II. Melanoma Cell Lines Contain Specific ER and 
Type II EBS" 
MNTl M1 0 M1 4 
Competitor'' ER EBS ER EBS ER EBS 
Diethylstilbestro l 21 ± 5 27 ::!: 5 32 ::!: 7 34 ± 4 45 ± 6 39 ± 7 
Progesterone 85 ± 10 81 ± 9 89 ± 5 88 ± 5 86 ± 9 82 ± 8 
5a -DHT 88 ± 10 82 ± 7 85 ± 4 80 ::!: 8 87 ::!: 8 80 ± 9 
Dexamethasone 94 ± 6 96 ± 8 98 ± 5 95 ± 6 97 ± 7 98 ± 3 
Tamoxifcn 39 ± 4 25 ± 6 40 ::!: 6 30 :!: 5 44 ± 8 40 ± 6 
IC I-1 82780 35 :!: 5 90 ± 8 37 ± 8 95 ::!: 5 46 ± 6 93 ::!: 8 
Quercetin 98 ± 5 22 ± 4 97 ± 7 29 ± 4 95 ± 9 42 ± 5 
Rutin 97 ± 6 91 ± 9 98 ± 6 94 ± 7 96 :!: 5 92 ± 8 
•• R esul ts arc expressed :1s percentage of binding in the absence of competitors 
(cmnro l binding). T he contro l values (dpru) for rh c c:1nccr cell lines were MNTI = 
1508 ::!: 141, MI O = 1310 :!: 160. ond Ml4 = 955 :!: 93 for ER.; MNT1 = 10,308 :!: 
1720. M I 0 = 7810 ::!: 860. ond M14 = 15.540 :': 1540 for type II EllS. Values ore 
e xpressed as mean ± SD of three d ifferent cxpcri.mcn ts. 
1
' All competing compo unds were a t I 00- or 250-fold molar excess relative to 
!' HI-estradiol concentrotions for ER. (2 nM) and type II EI3S (40 nM), respectively. 
DHT, dihydrotcstostcrouc. 
THE JOU RNAL OF INVESTIGAT IVE DERMATOLOGY 
ti.n co uld not be reversed by the addition of exogenous estrogens 
(data not shown) . T he inhibitory effects of quercetin , tamoxifen, 
and diethylstilbestrol were not attributable , in the range of concen-
trations used , to a cell-killing actio n of these substances . In fact, cell 
viability afte r 3 d of culture was m o re than 85% and did not diffe r 
between control and treated cel.l s. Furthermore, the growth-
mhibitory effects appeared to be reversible because afte r removal of 
quercetin, tamoxifen, or diethylstilbestrol from the culture m e -
dium , the treated cells proliferated again like untreated cells (data 
not shown) . 
To analyze further tbe antiproliferative effects of quercetin and 
tamoxi.fen , we tested the ability of these substan ces to inhibit 
colony formation in a clonogenic assay. As reported in Fig 3, the 
inhibitory activity of both compounds on colony formation paral-
le led that o n cell growth (Fig 2). As o bserved previously in human 
leukemic cell s [9] , a significa nt corre lation was observed b etween 
the clonogenic efficiency of the cell lines and the inhibitory ac tiv ity 
of quercetin and tam oxifen o n colony form ation, with the less 
inhibited cell l.i.ne (M14) having the most efficient clonogenic 
capacity (Fig 4). · 
Primary Tumors Express Type II EBS Nuclear and cytosolic 
type II EBS are expressed i..t1 appreciable amounts in primary 
melanoma samples (Fig 5). T he shapes of both the bindi..t1g curve of 
eHJ-estradi o l to type ll EBS and the Scatchard p lot of binding data 
closely resembl e th ose observed for cell lines. V alues of nuclear 
typ e II EBS were 10,420 fi11ol/mg DNA (KD = 18 nM) and 6980 
fi11o l/mg DNA (K0 = 16 nM) for pati ent A and pa tient B (Fig 5), 
respective ly. T he corresponding values for cytosolic type II EBS 
were 2920 fi11o l/ m g of protein (K 0 = 21 nM) and 1430 fino l/ m g 
of protein (K0 = 23 nM) . Low levels ofER (9 fmol/mg of protein; 
K 0 = 0.2 nM) were present on ly in the neoplastic tissue from 
patient A . 
In the presen ce of 10 mM dithiothreitol , the binding of eH]-
estradiol to type II EBS was red uced to approx imately 30% of the 
control (wi tho ut dithiothreito l) value (data not shown) . This 
sensitivity is si.n:lllar to that observed previously for type II EBS in 
rat uterus [2] and human colorectal [7] and ovarian [6] can cers . As 
with m elanoma cell lines, in prima.ry tumor samples quercetin and 
tamoxifen displaced [3 H]-estradio l from typ e ll EBS with a poten cy 
similar to that of diethyl sti lbestro l, whereas nonestrogenic steroids 
as well as IC I-182780 and rutin did not (Table III). 
DISCUSSION 
Our data indicate that human melanoma expressed a large number 
of type Il EBS. Quercetin and tamoxifen are able to compete with 
type II EBS with a potency simila r to that of estrogens. On the other 
hand, rutin, the rhamnosylglucoside of quercetin , and the pure 
antiestrogen IC I-1 82780 do not compete with estrogens for these 
sites. 
E R were also expressed by melanoma cel ls and, as expected , 
estrogens and the antiestrogens tamoxifen and lC I-182780 inter-
acted with these receptors, whereas quercetin and rutin did not (for 
review see [26]). Our resu lts and data from other reports indicate 
that despite the presence ofER., neither es trogens nor anties trogens 
at concentrations able to saturate these recepm rs had any effect on 
plating efficiency or prolifera tion of melanoma cell lines [27) . 
Only those substan ces (quercetin and tamoxifen, but no t TCI-
182780 and ruti..t1) that are ab le to interact with type II EBS exert a 
con centratio n-dependent growth-i..tu1ibito ry effect on melanoma 
cells. T his is in agreement with previous studi es showing that type 
II EBS m ediate the inhibitory effec ts of quercetin and other 
flavonol s [3,6,8 -11 ,22) and of tamoxifen [10,11] in human cancer 
cell lmes and primary tumors. 
For melanoma i.n particular, i11 11itro exposure of hamster m ela-
noma cel.l s to pharmacologic concentrations of e ither es tradio l or 
tamoxifen results in growth inhibition [28,29]. Furthermore, rela-
ti vely high tamoxifen concentrations (0. 5 !J.M) significantly d e-
creased colony formation in two ER-negative human me lanoma 
cell lines [30]. T lus ER-i..t1dependent i..t1hibitory activity of tamox-
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Figure 2. Tantoxifcn and quercetin inhibit ntclanoma cell growth. MNT1, MlO, and M14 cell s were plated at 1.04 ceUs/cm0 and after 18 h. the 
medium was replaced with fres h medium and the compounds were added at the inclicated concenu·ations from absolute-ethanol stock solutions. In both 
conttol and treated samples, the fina l ethanol concentration was ·1 'Yo (v/v) . Ce lls were cultured for another 48 h and the treatments were repeated 24 h later. 
Quadrupli cate hemocytometer counts of tripli ca te cultures were then performed . Cell numbers for ethanol-treated conu·ol cultures were '195,780 :!: 18,915, 
149,240 ± 13,650, and 75 ,110 :!: 6070 for Ml4, M10, and MNT1 cells, respectively. Results represent the mean :!: SD of four experiments. Closed circles. 
quercetin; open circles, ta n1 ox.ifcn ; closed squares, rutin; open sq11ares, lC l-·J 82780. 
ifen and related triphe nyl eth yle nes is suppo rted by several othe r 
lines of evide nce. T hese include the tamoxifen-induced growth 
inhibition of some ER-nega tive cell li n es [1 0,30] and of ER-
positive ca ncer cell lines maintained under serum-free conditio ns 
(i.e . , in the absen ce of exogen o us estrogen) ([31] and this report) 
a.n.d the clinical response to tamoxifen of a distinct proportion of 
patients w ith ER-negative breast tumors (26]. Fin ally, the inhibi-
tory effects of hig h tamoxifen con cen trations on ER-positive cells 
cannot be reversed by the addi t io n of exogenous estrogens, and 
these inhibitory effects are not related to the aflini ty of the 
anties trogen for ER ((32] and this report) . 
A basis for the ER-inde pendent growth- inhibitory effects of 
tamoxifen and other related compounds has been suggested re-
cen tly. Several g ro ups h ave shown that these compounds are potent 
inhibitors of prote in kinase C [3 1,32], w hich is known to play a ro le 
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Figure 3. Tamoxifen and quercetin inhibit th e clonogenic capacity 
of melanoma cells. A 1.-ml underlayer of 0.5'% agar in lscove-modified 
Dulbecco's medium with 1.0% FBS and the compounds to be tested (1 J.LM) 
was p lated in S-cm plastic Petri dishes. Ce ll s (1 X l 03 / ml) were suspended 
in 0.31XI agar in the sa1nc 1ncdiun1 containing quercetin (stripl•d bnrs), 
camoxifen (closed bars), JC I-182780 (opc11 bars) , and ru tin (dMted IJatc<). T he 
colonies (collection of 30 or more ce lls) were counted 10 d after plating. 
Colon y numbers in control cul tures were 34 ± 7, 70 ± ·1 0, and '144 :!: 19 
for MNTl , M 10, and M1 4 cell s, respectively. Results represent the mean ± 
SD of four experiments. 
in the sign a.l- induced cascad e involved in regulating proliferation in 
many cell types. However, the 50'Yo inhibito t-y concentrations for 
protein kin ase C activity recorded for tamoxifen and c hemica lly 
related compo unds were in the r<mgc of 15- 100 J.LM (33], far from 
those that we o bserved to b e efrective in inhibi ting cell growth . 
Moreover, in human malig nant g liomas, tamoxifen is m o re effec-
tive in inhibiting protein kinase C activity than cell growth [34]. 
Flavono.ids also interact w ith several enzymes, in cluding protein 
kin ase C (35]. Although it is possibl e that they m ay also act at this 
level, the effective con centrations of these in teractions are in the 
micromolar range (approximately 50 J.LM) . Conversely, both ta-
moxifen and quercetin inte ract with type II EllS <md inhibit the 
growth of m elan oma and other neoplastic cells at lower concen-
trations (6-11 ,22]. 
Tam oxifen and q uercetin share m any other properties. Among 
70 0 quercetin r=0.91 n=l2 p<O.OOOl 
,.--._ 
• tamoxifen r=0.94 n=l2 p<O.OOOI 
-0 
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Figure 4. The inltibitory activity of tamoxifen and q uercetin on 
MNTI, M10, and M14 cell lines is inversely correlated with the 
clonogenic efficiency of these cells. C ulture conditions are described in 
F ig 3. Tamoxifen (dosed rirclt!s) and quercetin (ope11 rircles) were used :It 
1-J.LM concentrations. Clonogenic efficiency = (number of colonics/ 1000 
plated cell s) X J 00. 
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Figure 5 . Pritnary melanonta expresses nuclear and cytosolic type 
ll EBS. O n e-milliliter aliquots of t issue h o m ogenate were la yered o nto 
1-m l pads of 1. 2 M su crose a n d centrifuged in a swing ing-b ucket rotor at 
7000 X g for 45 min at 4°C to o btain the nuclear fra c t io n . T h e cytosoli c 
fractio n was prepared b y ultrace ntri fugatio n at 65,000 X g for 30 min at 4 °C. 
Nuclear and cytosoli c prepa ration s were incubated (30°C for 60 m in) w ith 
17/3-[3 1-l j-estrad io l (4-60 nM) w ith o r w itho ut a 300-fo ld m o lar excess o f 
die th ylsti lbestro l to dete rmine tota l and no nspecific binding. Specifi c b ind-
ing as a function of tracer con cen tration , both n uclear (n) and cytoso li c (c). 
was calcul a ted as th e differe n ce be twee n tota l and n o nspecifi c binding. 
N o nspec ific binding was approximatel y 50'Y,, and 35% of rota! nuclea r and 
cytoso li c b ind ing, respectively . /J) and rf) Sca tcha rd p lo ts of data in (n) an d 
(r), respectively. C ircles, patient A; frirll r,~lrs , patient B. 
them are the capacity to induce apoptos is [36,37), to reverse the 
phenotype of m ul tidrug resistance [lo], ' and to interact in a hig hl y 
syne rgistic mannct· with cisplatin both iu 11 itro and il r t1i11o [18,38-
40]. Taken together, these observations suggest a ·common m ech-
anism o f action for these compounds, probably m ediated as in oth er 
systems [3,4 ,6-9,22] by an interaction w ith type II EBS. 
T hen again, the presence of type II EBS in cell lines and in 
specimens fro m patien ts helps substantiate the reported effective-
ness of tamoxifen, partic ul arly in ER-negative tumors, and suggests 
a potentia l ro le of q uercetin in the treatment of melanoma. T he i11 
11itro inhibitory effect of tamo xifen and its synergistic interaction 
with other dru gs arc compati ble w ith the concentratio ns that ca n be 
obtained in human plasma [41 J. In thi s con text, it also should be 
noted that a plasm a concen tra tio n of 12 J-1-M quercetin , which is 
hjgher than that efFective i11 11itro for inJ1jbition of melano m a ce iJ 
proli feration, was obtained after an in traveno us injection of100 mg 
w ithout any apparent side elfccts [42]. 
Although the early events after ligand-receptor inte ractio n are 
uncl ea r, it has been reported tha t tamoxifen and quercetin can 
T H E J OU RNAL 0 1' INV ESTIGATIVE DERMATOLOGY 
Table III. Human Melanoma Contains Specific Type II 
EBS" 
Competitors'' C ase Case 2 
Diethylsti lbestrol 51 60 
Progeste rone 90 84 
Sa-D l-IT 84 89 
Dcxan1ctll aso 11 C 94 97 
Tamoxifcn 55 66 
IC I-1 827!!0 100 98 
Q uerce tin 53 54 
Rutin 90 92 
" Results arc ex pressed as percentage of bindin g to cytosoli c prcpnratio ns in th e 
absence of competitors (contro l binding) . The contro l va lues were 26,270 dpm an d 
I H. 120 dpm fOr G ISC A and e<ISC 13. respecti vel y. 
1
' All competing compo unds were at 250-fo ld m olar excess re lati ve t.o I" HJ-cstJ·adio l 
co ncentratio ns (40 nM) . D I-IT, di hydro t:cstostcronc.. 
induce the production of transform ing g rowth factor-{3 [43 ,44]. 
Beca use this growth fa ctor inhi bits the growth of several tumors 
[43,44] , including melanoma, in both anim al and hum an systems 
[45-47), we h ypothesize that t ltis ma y be one of the m echanisms by 
which tamox ifen and quercetin inhibit melanoma cell growth . 
T lris work "'"' Sll fJJIOI't ed by n .~rn llf ji-om Co11siglio Nnzio 11nlc Riclrcrrlre, ji 11 nlized 
flroject A.C.R.O PF39 94.0 1098; /1)' grmlls fim ll M. U .. R.S.T.; tll lfl by" g rn111 
A. I.R..C. (PGN). 
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